What is Ukko?
Based in Palo Alto, CA, Ukko operates at the intersection of artificial intelligence and biotechnology, specializing in developing advanced solutions for food sensitivities. The company leverages cutting-edge AI to analyze complex biological data, aiming to provide personalized and effective strategies for individuals managing dietary restrictions and adverse reactions. Ukko's focus on food sensitivity positions it within the rapidly expanding health-tech and personalized nutrition markets, addressing a growing global concern for dietary wellness and precision health.
How much funding has Ukko raised?
Ukko has raised a total of $47.7M across 2 funding rounds:
Series A
$7.7M
Series B
$40M
Series A (2017): $7.7M with participation from Izhar Armony, Slow Ventures, Innovation Endeavors, Marc Benioff, and Khosla Ventures
Series B (2021): $40M led by Peak Bridge Ventures, Continental Grain Company, Leaps by Bayer, Skyviews Life Science, and Fall Line Capital
Key Investors in Ukko
Slow Ventures
Slow Ventures is an investment firm that appears to focus on companies with a long-term vision, potentially supporting Ukko's innovative approach to biotechnology and AI.
Innovation Endeavors
Innovation Endeavors is a venture capital firm that typically invests in companies leveraging technology to address significant global challenges, aligning with Ukko's mission in food sensitivity solutions.
Continental Grain Company
Continental Grain Company, through its investment arm S2G Ventures, is a significant player in agribusiness and food technology, indicating a strategic interest in Ukko's biotech solutions for the food sector.
What's next for Ukko?
The recent major strategic investment of $40M positions Ukko for significant expansion and further development of its AI-powered food sensitivity platform. This capital infusion, part of its $47.7M in total funding, will likely fuel advancements in research and development, enhance its technological infrastructure, and broaden its market reach. As Ukko moves beyond its early-stage development, this funding suggests a transition towards scaling operations and potentially commercializing its solutions, aiming to establish itself as a leader in the personalized health and biotechnology space.
See full Ukko company page
